Literature DB >> 20139499

Erythropoietin can promote survival of cerebral cells by downregulating Bax gene after traumatic brain injury in rats.

Z B Liao1, G Y Jiang, Z H Tang, X G Zhi, X C Sun, W Y Tang, M J Wu.   

Abstract

BACKGROUND: Traumatic brain injury (TBI) is an important cause of adult mortality and morbidity. Erythropoietin (Epo) has been shown to promote the viability of cerebral cells by upregulating Bcl-2 gene; however, Epo may exert its antiapoptotic effect via the differential regulation of the expression of genes involved in the apoptotic process. AIM: The present study examined the neuroprotective effect of Epo as a survival factor through the regulation of the Bax.
MATERIALS AND METHODS: Wistar rats were randomly divided into three groups: Recombinant human EPO treated (rhEPO) TBI, vehicle-treated TBI, and sham-operated. Traumatic brain injury was induced by the Feeney free-falling model. Rats were killed 5, 12, 24, 72, 120, or 168 h after TBI. Regulation of Bcl-2 was detected by reverse transcription-polymerase chain reaction (RT-PCR), western blotting and immunofluorescence.
RESULTS: Bax mRNA and protein levels were lower in the rhEPO)-treated rat brains than in the vehicle-treated rat brains. Induction of Bax expression peaked at 24 h and remained stable for 72-120 h in vehicle-treated rat brains, whereas induction of Bax expression was only slightly elevated in rhEPO-treated rat brains. The number of TdT-mediated dUTP Nick-End Labeling(TUNEL)-positive cells in the rhEPO-treated rat brains was far fewer than in the vehicle-treated rat brains.
CONCLUSIONS: Epo exerts neuroprotective effect against traumatic brain injury via reducing Bax gene expression involved in inhibiting TBI-induced neuronal cell death.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20139499     DOI: 10.4103/0028-3886.59466

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  6 in total

Review 1.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

Review 2.  Hemorrhagic progression of a contusion after traumatic brain injury: a review.

Authors:  David Kurland; Caron Hong; Bizhan Aarabi; Volodymyr Gerzanich; J Marc Simard
Journal:  J Neurotrauma       Date:  2011-12-05       Impact factor: 5.269

Review 3.  Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup.

Authors:  Ramon Diaz-Arrastia; Patrick M Kochanek; Peter Bergold; Kimbra Kenney; Christine E Marx; Col Jamie B Grimes; L T C Yince Loh; L T C Gina E Adam; Devon Oskvig; Kenneth C Curley; Wanda Salzer
Journal:  J Neurotrauma       Date:  2014-01-15       Impact factor: 5.269

4.  Erythropoietin improved cognitive function and decreased hippocampal caspase activity in rat pups after traumatic brain injury.

Authors:  Michelle E Schober; Daniela F Requena; Benjamin Block; Lizeth J Davis; Christopher Rodesch; T Charles Casper; Sandra E Juul; Raymond P Kesner; Robert H Lane
Journal:  J Neurotrauma       Date:  2014-02-15       Impact factor: 5.269

Review 5.  Neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection?

Authors:  Dominique Lerouet; Catherine Marchand-Leroux; Valérie C Besson
Journal:  Fundam Clin Pharmacol       Date:  2021-03-13       Impact factor: 2.747

6.  Endothelial nitric oxide synthase mediates the cerebrovascular effects of erythropoietin in traumatic brain injury.

Authors:  Jovany Cruz Navarro; Shibu Pillai; Lucido L Ponce; Mai Van; Jerry Clay Goodman; Claudia S Robertson
Journal:  Front Immunol       Date:  2014-10-09       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.